Dottikon ES Holding Past Earnings Performance
Past criteria checks 2/6
Dottikon ES Holding has been growing earnings at an average annual rate of 30.5%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been growing at an average rate of 17.9% per year. Dottikon ES Holding's return on equity is 10.2%, and it has net margins of 25.5%.
Key information
30.5%
Earnings growth rate
28.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 16.3% |
| Revenue growth rate | 17.9% |
| Return on equity | 10.2% |
| Net Margin | 25.5% |
| Next Earnings Update | 28 May 2024 |
Recent past performance updates
Recent updates
Subdued Growth No Barrier To Dottikon ES Holding AG's (VTX:DESN) Price
Mar 31
Does Dottikon ES Holding (VTX:DESN) Deserve A Spot On Your Watchlist?
Feb 17Earnings Not Telling The Story For Dottikon ES Holding AG (VTX:DESN)
Dec 26Dottikon ES Holding (VTX:DESN) Is Doing The Right Things To Multiply Its Share Price
Nov 10Here's Why We Think Dottikon ES Holding (VTX:DESN) Is Well Worth Watching
Oct 25These 4 Measures Indicate That Dottikon ES Holding (VTX:DESN) Is Using Debt Reasonably Well
Sep 19At CHF217, Is It Time To Put Dottikon ES Holding AG (VTX:DESN) On Your Watch List?
Aug 20If EPS Growth Is Important To You, Dottikon ES Holding (VTX:DESN) Presents An Opportunity
Jul 20Returns Are Gaining Momentum At Dottikon ES Holding (VTX:DESN)
Jul 05Here's Why Dottikon ES Holding (VTX:DESN) Can Manage Its Debt Responsibly
Jun 17Is It Too Late To Consider Buying Dottikon Es Holding AG (VTX:DESN)?
Apr 07Dottikon Es Holding's (VTX:DESN) Returns Have Hit A Wall
Mar 22Should You Be Adding Dottikon Es Holding (VTX:DESN) To Your Watchlist Today?
Mar 06Is It Too Late To Consider Buying Dottikon Es Holding AG (VTX:DESN)?
Jan 04Dottikon Es Holding (VTX:DESN) Has More To Do To Multiply In Value Going Forward
Dec 19Does Dottikon Es Holding (VTX:DESN) Deserve A Spot On Your Watchlist?
Dec 02What Does Dottikon Es Holding AG's (VTX:DESN) Share Price Indicate?
Sep 20Here's What To Make Of Dottikon Es Holding's (VTX:DESN) Decelerating Rates Of Return
Sep 02Why Dottikon Es Holding AG (VTX:DESN) Could Be Worth Watching
Jun 20The Returns At Dottikon Es Holding (VTX:DESN) Aren't Growing
Jun 02Does Dottikon Es Holding (VTX:DESN) Deserve A Spot On Your Watchlist?
Apr 11When Should You Buy Dottikon Es Holding AG (VTX:DESN)?
Mar 09Dottikon Es Holding (VTX:DESN) Has More To Do To Multiply In Value Going Forward
Feb 23Do Dottikon Es Holding's (VTX:DESN) Earnings Warrant Your Attention?
Dec 30Dottikon Es Holding's (VTX:DESN) Returns On Capital Are Heading Higher
Nov 24When Should You Buy Dottikon Es Holding AG (VTX:DESN)?
Sep 28Does Dottikon Es Holding (VTX:DESN) Deserve A Spot On Your Watchlist?
Sep 02We Like These Underlying Return On Capital Trends At Dottikon Es Holding (VTX:DESN)
Aug 17When Should You Buy Dottikon Es Holding AG (VTX:DESN)?
Jun 15Here's Why I Think Dottikon Es Holding (VTX:DESN) Is An Interesting Stock
Jun 01Dottikon Es Holding (VTX:DESN) Is Experiencing Growth In Returns On Capital
May 17Could The Dottikon Es Holding AG (VTX:DESN) Ownership Structure Tell Us Something Useful?
Mar 20Is Now The Time To Put Dottikon Es Holding (VTX:DESN) On Your Watchlist?
Mar 01Here’s What’s Happening With Returns At Dottikon Es Holding (VTX:DESN)
Feb 08
If You Had Bought Dottikon Es Holding (VTX:DESN) Shares Five Years Ago You'd Have Earned 856% Returns
Jan 18Is Dottikon Es Holding AG's (VTX:DESN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 29With EPS Growth And More, Dottikon Es Holding (VTX:DESN) Is Interesting
Nov 30Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Dottikon ES Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 338 | 86 | 87 | 0 |
| 30 Jun 23 | 331 | 87 | 85 | 0 |
| 31 Mar 23 | 319 | 88 | 84 | 0 |
| 31 Dec 22 | 302 | 81 | 81 | 0 |
| 30 Sep 22 | 284 | 74 | 78 | 0 |
| 30 Jun 22 | 268 | 67 | 77 | 0 |
| 31 Mar 22 | 252 | 59 | 77 | 0 |
| 31 Dec 21 | 240 | 57 | 77 | 0 |
| 30 Sep 21 | 229 | 55 | 77 | 0 |
| 30 Jun 21 | 224 | 54 | 76 | 0 |
| 31 Mar 21 | 219 | 52 | 75 | 0 |
| 31 Dec 20 | 204 | 46 | 73 | 0 |
| 30 Sep 20 | 189 | 39 | 71 | 0 |
| 30 Jun 20 | 182 | 36 | 70 | 0 |
| 31 Mar 20 | 175 | 33 | 69 | 0 |
| 31 Dec 19 | 172 | 31 | 69 | 0 |
| 30 Sep 19 | 169 | 30 | 69 | 0 |
| 30 Jun 19 | 158 | 23 | 68 | 0 |
| 31 Mar 19 | 148 | 16 | 67 | 0 |
| 31 Dec 18 | 147 | 17 | 66 | 0 |
| 30 Sep 18 | 145 | 18 | 65 | 0 |
| 30 Jun 18 | 153 | 22 | 65 | 0 |
| 31 Mar 18 | 161 | 26 | 64 | 0 |
| 31 Dec 17 | 159 | 24 | 60 | 0 |
| 30 Sep 17 | 157 | 22 | 56 | 0 |
| 30 Jun 17 | 156 | 22 | 55 | 0 |
| 31 Mar 17 | 155 | 22 | 53 | 0 |
| 31 Dec 16 | 151 | 22 | 55 | 0 |
| 30 Sep 16 | 148 | 23 | 57 | 0 |
| 30 Jun 16 | 136 | 19 | 55 | 0 |
| 31 Mar 16 | 123 | 14 | 54 | 0 |
| 31 Dec 15 | 113 | 10 | 52 | 0 |
| 30 Sep 15 | 102 | 5 | 51 | 0 |
| 30 Jun 15 | 100 | 3 | 50 | 0 |
| 31 Mar 15 | 98 | 1 | 48 | 0 |
| 31 Dec 14 | 95 | 0 | 47 | 0 |
| 30 Sep 14 | 91 | -1 | 46 | 0 |
| 30 Jun 14 | 91 | -2 | 46 | 0 |
| 31 Mar 14 | 92 | -3 | 46 | 0 |
| 31 Dec 13 | 89 | -5 | 46 | 0 |
| 30 Sep 13 | 87 | -7 | 46 | 0 |
| 30 Jun 13 | 86 | -7 | 45 | 0 |
Quality Earnings: DESN has a high level of non-cash earnings.
Growing Profit Margin: DESN's current net profit margins (25.5%) are lower than last year (26.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DESN's earnings have grown significantly by 30.5% per year over the past 5 years.
Accelerating Growth: DESN's earnings growth over the past year (16%) is below its 5-year average (30.5% per year).
Earnings vs Industry: DESN earnings growth over the past year (16%) exceeded the Pharmaceuticals industry -7.4%.
Return on Equity
High ROE: DESN's Return on Equity (10.2%) is considered low.